ARS Pharmaceuticals (SPRY) is now covered by Northland Securities. They set an "outperform" rating and a $25.00 price target on the stock.
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label [Yahoo! Finance]
ARS Pharmaceuticals Receives FDA Approval to Remove Age Requirement From neffy® 1 mg (epinephrine nasal spray) Label
ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines [Seeking Alpha]
ARS Pharmaceuticals (SPRY) was given a new $26.00 price target by Leerink Partners.